<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03939026</url>
  </required_header>
  <id_info>
    <org_study_id>ALLO-501-201</org_study_id>
    <nct_id>NCT03939026</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma</brief_title>
  <acronym>ALPHA</acronym>
  <official_title>A Single-Arm, Open-Label, Phase 1 Study Evaluating the Safety, Efficacy, and Cellular Kinetics/Pharmacodynamics of ALLO-501, an Anti-CD19 Allogeneic CAR T Cell Therapy, And ALLO-647, An Anti-CD52 Monoclonal Antibody, in Patients With Relapsed/Refractory Large B-Cell Lymphoma or Follicular Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Allogene Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Allogene Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ALPHA study is to assess the safety, efficacy, cell kinetics and&#xD;
      immunogenicity of ALLO-501 in adults with relapsed or refractory large B-cell lymphoma or&#xD;
      follicular lymphoma after a lymphodepletion regimen comprising fludarabine, cyclophosphamide,&#xD;
      and ALLO-647.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Anticipated">September 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects experiencing Dose Limiting Toxicities at increasing doses of ALLO-501</measure>
    <time_frame>28 days</time_frame>
    <description>Dose limiting toxicity is defined as protocol-defined ALLO-501-related adverse events with onset within 28 days following infusion</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients experiencing Dose Limiting Toxicity with ALLO-647 in combination with fludarabine/cyclophosphamide administered prior to ALLO-501</measure>
    <time_frame>33 days</time_frame>
    <description>Dose-limiting toxicity is defined as protocol-defined ALLO-647-related adverse events with onset within 33 days following 1st infusion</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">74</enrollment>
  <condition>Relapsed/Refractory Large B Cell Lymphoma</condition>
  <condition>Relapsed/Refractory Follicular Lymphoma</condition>
  <arm_group>
    <arm_group_label>ALLO-647, ALLO-501</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>ALLO-501</intervention_name>
    <description>ALLO-501 is an allogeneic CAR T cell therapy targeting CD19</description>
    <arm_group_label>ALLO-647, ALLO-501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ALLO-647</intervention_name>
    <description>ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen</description>
    <arm_group_label>ALLO-647, ALLO-501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-501</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Chemotherapy for lymphodepletion</description>
    <arm_group_label>ALLO-647, ALLO-501</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological or cytological diagnosis of Large B-cell Lymphoma (LBCL) or Follicular&#xD;
             Lymphoma.&#xD;
&#xD;
          -  Relapse or refractory disease after at least 2 lines of chemotherapy&#xD;
&#xD;
          -  At least 1 measurable lesion at time of screening.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1.&#xD;
&#xD;
          -  Adequate hematological, renal, liver, pulmonary, and cardiac functions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Current or history of central nervous system (CNS) lymphoma.&#xD;
&#xD;
          -  Clinically significant CNS dysfunction.&#xD;
&#xD;
          -  ASCT within last 6 weeks or allogeneic HSCT within last 3 months prior to ALLO-647.&#xD;
&#xD;
          -  Prior treatment with anti-CD19 therapy, any gene therapy, any genetically modified&#xD;
             cell therapy or adoptive T cell therapy&#xD;
&#xD;
          -  Systemic anticancer therapy within 2 weeks prior to study entry.&#xD;
&#xD;
          -  On-going treatment with immunosuppressive agents.&#xD;
&#xD;
          -  Active acute or chronic graft versus host disease (GvHD), or GvHD requiring&#xD;
             immunosuppressive treatment within 4 weeks of enrollment.&#xD;
&#xD;
          -  Any form of primary or acquired immunodeficiency (e.g., severe combined&#xD;
             immunodeficiency disease).&#xD;
&#xD;
          -  Current thyroid disorder (including hyperthyroidism), except for subjects with&#xD;
             hypothyroidism controlled on a stable dose of hormone replacement therapy.&#xD;
&#xD;
          -  Patients unwilling to participate in an extended safety monitoring period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Colorado Blood Cancer Institute</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80218</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Moffitt Cancer Center</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Davids South Austin Medical Center</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 4, 2019</study_first_submitted>
  <study_first_submitted_qc>May 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2019</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CAR T</keyword>
  <keyword>Cell Therapy</keyword>
  <keyword>Allogeneic Cell Therapy</keyword>
  <keyword>Cellular Immuno-therapy</keyword>
  <keyword>AlloCAR T</keyword>
  <keyword>ALLO-501</keyword>
  <keyword>ALLO-647</keyword>
  <keyword>LBCL</keyword>
  <keyword>Lymphoma</keyword>
  <keyword>Follicular Lymphoma</keyword>
  <keyword>Large B-Cell Lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, Follicular</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

